Introduction
Graves' disease is an autoimmune disease characterized by hyperthyroidism, goiter and extrathyroidal manifestations, such as exophthalmos [1, 2] . Autoantibodies to the TSH receptor (TSHR) have been detected in patients with Graves' disease and stimulating antibodies to TSHR are believed to induce hyperthyroidism [3, 4] . Therefore, TSHR and anti-TSHR antibodies (TSHRAb) play a key role in this disease.
In our previous review, we described studies on the cloning and analysis of both TSHR and TSHRAb genes [5] . This study aimed to clarify the structure, function and interaction of TSHR and TSHRAb at the molecular level. In the present review, we summarize results of recent extended molecular analysis of TSHRAb. In addition, we refer to genetic components in Graves' disease, a disease in which multiple genetic and environmental factors are thought impair immunoregulation.
Causes of Graves' Disease
There is a growing consensus that Graves' disease, similar to other autoimmune diseases, is multifactorial: many factors interact and produce the clinical phenotype of this disease ( Fig. 1 ).
Genetic factors
Graves' disease is a complex disease with a significant genetic component as shown by twin studies [6] and familial aggregation, including clustering within families [7, 8] . While the genetic basis of Graves' disease is unclear, it is believed to be polygenic.
Several genetic factors associated with Graves' disease susceptibility have been identified, including sex (a five-fold higher prevalence in females), the HLA genes on chromosome 6p [9] , the immunoglobulin heavy chain gene constant region, Gm, on 14g32.2 [9] , a point mutation at codon 52 of the TSHR gene on 14g31 [10] , the CTLA-4 gene region on 2g33 [11] , and the interleukin-1 receptor antagonist gene [12] . The HLA Class II association with Graves' disease has been observed in Japanese [9] , Caucasian and Chinese [13] populations. In common with some other autoimmune diseases,, there is strong association with HLA-DR3 [13] [14] [15] , but other HLA associations with Graves' disease have shown a lack of consistency between populations [9, 13] . Roman et al. [16] observed association but no linkage between the HLA region and Graves' disease in a Caucasian population, and suggested that HLA may increase susceptibility to Graves' disease but the major genetic influence on the inheritance may lie at another locus.
Theories of autoimmunity fall into four main categories: primary immune dysregulation, failure of idiotype control, molecular mimicry, and primary lesion theory [17] . Some combine two of these, and they almost certainly overlap. In the primary lesion theory, it has been hypothesized that a change in an antigen may trigger a response in a normal immune system [17] , or that a proportion of the population carries a slightly altered form of an antigen which, when combined with other genetic and environmental factors, may result in the disease phenotype [18] . TSHR is an autoantigen found in many autoimmune thyroid diseases (AITD) patients, and an association has already been observed between a point mutation of TSHR and AITD susceptibility. We have recently investigated the genetic contribution of TSHR to AITD susceptibility in the Japanese [19, 20] . While the gene for TSHR has been cloned [5] and localized to 14g31 [21-23], it was not genetically mapped previously. Development of a microsatellite marker for the TSHR gene is essential for evaluating its role in populations with AITD through association and linkage analyses. Therefore, we isolated a yeast artificial chromosome containing part of the TSHR gene and identified a dinucleotide repeat polymorphism near the TSHR gene (heterozygosity = 0.67 in the Japanese). This microsatellite mapped to an 8.6 cM interval between D14S74 and D14555 on the long arm of the TSHR gene (heterozygosity = 0.67 in the Japanese). Next, the microsatellite marker we identified has been used to assess the genetic contribution of the TSHR gene to AITD in a population of Japanese patients. Association studies were performed between the TSHR microsatellite and a population of 81 unrelated Japanese AITD patients. A significant increase in the frequency of allele 1 (180bp) was observed in the AITD population when compared with 50 male Japanese controls (P=5.9 x 10-8). This association was highly significant in the female patients (n=63; P=1.8 x.10-6) and near significant in males. When the data was stratified into AITD type (Graves' disease, hypothyroid patients with thyrotropin stimulation blocking antibodies (BAb), or Hashimoto's Thyroiditis (HT)), HT (n=18; P=4.9 x 10-10) and BAb (n=20; P=0.0004) but not Graves' disease showed a significant association with allele 1. These results suggest that allele 1 of the TSHR microsatellite is associated with susceptibility for AITD except Graves' disease in Japanese patients.
Point mutations have been identified in putative ligand binding regions of the extracellular domain of the TSHR gene in patients with Graves' disease [24] [25] [26] , and these mutations may produce autoantigens involved in the pathogenesis of the disease. A mutation in the first position of codon 52, resulting in the substitution of a threonine for a proline in the extracellular domain of the TSHR protein, has been shown to be significantly associated with AITD in Caucasian females [25, 26] . However, the TSHR codon 52 point mutation was not detected in any of the 81 Japanese AITD patients or the 113 Japanese controls [20] .
In addition, an association has been observed between a polymorphism in the cytotoxic T lymphocyte associated-4 (CTLA-4) gene and susceptibility to Graves' disease in Caucasians [11] , with greater significance seen in females with the disease and protective HLA genotypes. Nistico et al. [27] found supporting evidence that CTLA-4 is associated with susceptibility to GD in Hong Kong Chinese Graves' patients. The CTLA-4 molecule, which is co-expressed with CD28 on activated Tcells, interacts with B7 on antigen-presenting cells to stimulate T-cell proliferation. CTLA-4 and CD28 appear to have very similar functions [28] and their genes are located at a distance of only 25-150 kb on 2g33 [29] , so susceptibility to AITD may be associated with either of these genes or another nearby locus also in linkage disequilibrium.
A recent finding revealed that CTLA-4 alanine-17 confers genetic susceptibility to Graves' disease and to type 1 diabetes mellitus [30] . We also evaluated Japanese AITD patients and controls for association with the CTLA-4 polymorphism [20] . While association with AITD was not observed (P=0. 15 Multiple factors including infection, stress, sex steroids, pregnancy, aging and food, are known as environmental factors precipitating Graves' disease [1] . Structural similarity between infectious agents and TSHR can lead to crossover of specificity, molecular mimicry. In fact, specificity crossover has been reported between Yersinia enterocolitica and TSHR, based on the cross-reaction between Yersinia and serum from patients with Graves' disease as well as between retroviral sequences and the TSHR [1] . Regarding stress, Benvenga reported that adjunctive benzodiazepine therapy with use of antithyroid drugs decreased the incidence of relapse of the disease [31] . A large prospective study on the value of benzodiazepine in the treatment of Graves' disease is needed. [39] . Thus, we prepared and analyzed a series of IgG-class and IgM-class monoclonal antibodies obtained from patients with Graves' disease and primary hypothyroidism.
In previous studies using Graves' lymphocytes, surprisingly, all clones producing IgM class antibodies showed either TBII or TSAb activity, never both [5, 37] . This supports the view that TBII and TSAb are different immunoglobulins. This was the case in IgG class TSAbs [39, 40] . In contrast, in studies using lymphocytes of hypothyroid patients,, all 20 TBII positive clones obtained were positive for TSBAb activity [38] . Only two TSBAb positive clones had negative TBII activity. Although there was no significant relationship between TBII and TSBAb activity, most TBIIs and TSBAbs appear to overlap.
In sum, these findings suggest that TBII in Graves' patients is different from TSAb but in myxedema patients closely overlaps with TSBAb.
Next, we attempted to elucidate the relationship between TBII and TSBAb in Graves' patients. Five
IgM class monoclonal TBII previously prepared [37] from Graves' patients were used (Table 1 ) (J. Okuda and T. Akamizu, manuscript in preparation). They were isolated from EB virus-transformed lymphocytes of a patient with Graves' disease. Clone 267-1 is a sister clone of 267-9, which was confirmed by Southern blot analysis [37] . Neither is known to have TSAb activity [37] . TSBAb activity was determined by a previously described method [38] . As shown in Table 1 , 4 of 5 TBII clones had TSBAb activity. Since the normal range of TSBAb was determined to be less than 24% (mean + 2SD: 4.0 + 20%), Clone 296-4 showed borderline activity, 21.3%. The TSBAb activity in Graves' patients with TBII tended to be lower than that in hypothyroid patients. There was no significant relationship between TBII and TSBAb activity (n=5, r=0.059). These findings do not contradict other reports using monoclonal TRAb obtained from Graves' patients [42] [43] [44] . For example, Valente et al. [42] found that potent TBIIs were TSBAbs and that TSAbs were poor TSH binding inhibitors, and Yoshida et al. [43] reported that there existed TSBAb with and without TBII, although they studied only a limited number of monoclonal TSHRAb. Our previous study using monoclonal antibodies obtained from lymphocytes of hypothyroid patients revealed that all TBII clones had TSBAb activity and all but two TSBAb clones showed TBII activity, although TBII and TSBAb activity was not significantly correlated. These findings suggested that most TBII appear to be TSBAb. In contrast, lymphocytes from Graves' patients produced either TSAb or TBII, and never both. Considering that other investigators detected a small number of clones with both TBII and TSAb [43, 45] , we postulate here a relationship between the binding inhibitors (TBII) and the biologically heterogeneous antibodies (TSBAb and TSAb) as shown in Fig. 2 . This schema is compatible with the clinical observation that TBII was altered together with TSBAb rather than TSAb in most patients with Graves' disease who developed hypothyroidism during the clinical course [46] [47] [48] . Although we used IgM class TBII in this study, we did not observe any difference by isotypes in the relationship between TSAb and TBII [39, 40] , or TSBAb and TBII [38] .
Our patients were of VH_III, while those from patients with primary hypothyroidism were less restricted, and included VH_II, -III, and _iv. TSAb genes were diverse and were of VH-II, -III, -IV and -v ( Table 3) . The most homologous germ-line VH segments of these antibodies have been used frequently in autoantibodies or in the fetal repertoire (Table 4) [5, 40, 41] . For example, V3-7, a germ-line VH counterpart of TBII (296-4), TSAb (101-2) and TSBAb (31-3), was reported to be expressed in fetal liver. The germ-line counterpart VH segment (V3-23) of 291-11, 267-9, 79-4 and 22-1 was also used in 18/2, an anti-DNA antibody, and 30P1 cDNA is found in fetal liver. Similarly, the germ-line VH segment of 82-1, N-2 and B6B7 is V4-59 which is 99.4% homologous to 58P2, frequently expressed during the early stage of ontogeny, and 98.6% identical to Pag-1, an autoantibody for D-Ag of the Rh blood group system.
In VK genes, all TSBAb genes were of VK_m, while TSHRAb genes from patients with Graves' disease, c) Production of recombinant TSHRAb Next, we aimed to produce recombinant TSHRAb proteins [40] . For this purpose, we isolated V region cDNAs of both H and light chains of 1gM and IgG TSHRAbs from B cell clones including those already established [37, 38] . Each pair of H-and L-chain cDNAs was ligated into novel expression vectors for IgGI production and introduced into myeloma cells (Fig. 3) [40] . In two transfectants, derived from B6B7 and 101-2 clone, recombinant IgGI antibodies with significant TSAb activities were successfully obtained (Fig. 4) [40] . The TSAb activity is reported to be confined to the IgGI fraction of patient's serum [511. IgGs derived from B6B7 and 101-2 Ig gene transfectants exhibited significant TSAb activity in FRTL-5 cells, while IgG derived from transfectants with an indifferent Ig gene did not. The results were reproduced in TSAb assays using CHO cells transf ected with rat TSHR cDNA.
The supernatant of B6B7 transfectant gave significant TSAb activity between the IgG concentrations of 15-240 µg/ml, with maximal activity obtained at around 30 µg/ml [40] . The range of maximal TSAb activity of B6B7 in four experiments was 186-302 (mean ± SD: 239 ± 41)%. This activity was not only very similar to that of the supernatant of original EBV-transformant (202-285 (mean ± SD: 240 ± 34) %, [39] ), but also appeared to reflect that of the patient serum (263% [39] ). When the VH region of B6B7 in the construct was replaced with an unrelated VH region, which utilized the same germline VH (V4-59) yet different DH and JH, TSAb activity was lost. On the other hand, TSAb activity of 101-2 IgG was observed between 10 to 80 ug/ml. Of note, the range of maximal TSAb activity at around 15 ,ug/ml in four experiments was 181-239 (mean ± SD: 212 ± 24)%, and slightly lower than that of the original EBV transformant (334%). This might be due to the alteration of isotype from IgM to IgGI.
The level of TSAb activity was dose-dependent in both clones and TSAb activity levels decreased at higher IgG concentrations than the maximal point. Thus, in both antibodies, dose-dependency curves of TSAb activities were bell-shaped, although the implications of this phenomenon remain unclear. We tested whether or not these TSAbs also possessed TBII activity. No TBII activity was detected even at the IgG concentrations that gave significant TSAb activity, in agreement with the results obtained in the supernatants of EBV transformants, indicating that TSAb and TBII activities are derived from separate B lymphocyte clones [40] .
Genetic engineering of monoclonal TSAbs enables large amounts of TSAb protein to be produced. Since the TSAbs isolated here were derived from patient lymphocytes, they should prove useful as a biological standard for TSAbs in various fields of research and facilitate pathophysiological studies on TSHRAbs in autoimmune thyroid diseases. An outline of the isolation of VH and VK genes from mRNAs of B cell clones, and construction of recombinant Ig genes [40] . UT, untranslated region; L, leader; V, variable; D, diverse; J, joining; C, constant; AAAA, poly A tail; SRa, SRa promoter; heavy line, exon; E, EcoRI; B, BamHI; H, HindIII; X, XhoI. AKAMIZU et al.
Others a) T cell
It is important to define T cell epitopes on TSHR, since it is expected to lead to further understanding of the pathogenesis of Graves' disease and to new developments in immunotherapy.
Little is known, however, about T cell recognition of TSHR [5] . Although the existence of multiple T cell epitopes on the receptor is suggested, no definite epitopes have been determined to date.
Recently, subsets of CD4+ helper T cells distinguishable by the cytokines they produce have been described: Th1 cells that produce interleukin (IL)-2, interferon (IFN) y and tumor-necrosis factor (TNF)-f3, and Th2 cells that produce IL-4, IL-5, IL-6 and IL-13 [52, 53] b) Cytokines and costimulatory molecules Associations between T-cell subset cytokine expression patterns and autoimmune diseases underscore the critical roles played by cytokines in controlling pathological immune responses [52, 53] . IL-4 and IL-13 faciliate a Th2 response resulting in antibody synthesis and IL-4 itself is a key cytokine product of Th2 cells for this response. A recent study showed the majority of thyroid tissue specimens obtained from Graves' patients expressed these cytokines [54] .
Interactions between the B7s (B7-1 and B7-2) on antigen-presenting cells and CD28 or CTLA4 on T cells are important for T cell activation; CD28 plays a critical role for preventing T cell unresponsiveness, while CTLA-4 is supposed to be a negative regulator of ongoing immune responses, although it is not clear how such costimulatory interactions influence on a response of either Th1 or Th2 [55] . Additionally, costimulatory molecules are reported to be important for antigen presentation by follicular cells that express MHC class II molecules aberrantly in autoimmune diseases [55] . [56] . They developed hyperthyroidism with the major humoral and histological features of Graves' disease. However, this model is not inheritable. In this regard, an animal model in which the disease is genetically programed is awaited. For this purpose, we hope to introduce immunoglobulin genes into transgenic mice, since a similar attempt succeeded in a model of autoimmune hemolytic anemia [57, 58] .
Finally, the pathogenesis of extrathyroidal manifestations has yet to be clarified. There have been several reports demonstrating TSHR transpripts, TSHR protein or a cross-reacting protein in a variety of extratyroidal tissues, including ocular tissue, dermal firbroblasts, lymphocytes, skeletal muscle and heart [59] [60] [61] [62] . It is, however, not clear how TSHR plays a role as the antigenic link between the thyroid and other tissues which might explain the frequent association of Graves' disease and extrathyroidal manifestations. The mechanism for the association of these disorders with TSHR for antibodies and T lymphocytes in the involved tissues has to be elucidated. marker 
